Induction of Abortion in the Second Trimester

Use Of Hyoscine as An Adjuvant Treatment on Shortening the Time of Abortion Induction in Second Trimester: Randomized Controlled Clinical Trial

NCT06207539•Ain Shams Maternity Hospital

View on ClinicalTrials.gov

Summary

To compare between the effects of misoprostol with hyoscine N-butyl bromide and misoprostol alone on shortening the time of abortion induction in the second trimester.

Detailed Description

The study will be conducted on 40 women who will undergo induction of abortion between 13-24 weeks with positive fetal pulsation. They will be randomly assigned to receive either only misoprostol 400 μg under the generic name of misotac tablets produced by Sigma company according to FIGO classification 2019 and a halved dose if the patient has a history of one or two cesarean sections, or misoprostol 400 μg plus intramuscular administration of hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company.

Eligibility

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. Abortion between 13-24 weeks with positive fetal pulsation due to congenital fetal malformations, severe preeclampsia, and maternal life-threatening conditions.
•2. Women have up to two cesarean sections.

Exclusion Criteria

•1. Abortion between 13-24 weeks with no fetal pulsation
•2. Women who have had two or more caesarean sections.
•3. Multiple pregnancies
•4. Uterine anomalies, such as septate and didelphis uteri.

Locations (1)

Ain Shams University

Cairo, Egypt

Key Dates

Start Date

December 1, 2022

Primary Completion Date

March 30, 2023

Completion Date

April 30, 2023

Last Updated

January 17, 2024

Enrollment

ACTUAL participants

Conditions

Abortion, Second Trimester

Interventions

hyoscine N-butyl bromide under the generic name of buscopan ampoule produced by Sanofi company

DRUG

misoprostol under the generic name of misotac tablets

DRUG

Uterocervical Angle in the Termination of Second Trimester Pregnancy

NCT03220607

Abortion, Second Trimester

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 17, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions